Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220382 · ClinicalTrials.gov registry record · Phase 4
Preoperative BOTOX® Injection for Large Ventral Hernia Repair
A Phase 4 study of Hernia and Hernia Abdominal Wall, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 188
- Enrollment target
- 1
- Study location
NCT07220382: Recruiting Phase 4 study of Hernia and Hernia Abdominal Wall, sponsored by The Cleveland Clinic.
NCT07220382 is a Phase 4 study of Hernia and Hernia Abdominal Wall that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 188 participants, roughly in line with the 186-participant average among 11 other Hernia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220382, a Phase 4 study of Hernia and Hernia Abdominal Wall, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 188 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for adults who need open surgery to repair a very large abdominal (ventral) hernia. This study tests whether a one-time, image-guided injection of a medicine commonly known as "BOTOX®" (onabotulinumtoxinA) into the side abdominal muscles 3-7 weeks before surgery helps surgeons close the abdominal wall fully at the end of the operation. Closing the muscle and tissue layers ("primary fascial closure") is linked to fewer problems after surgery and better quality of life. Participants will be randomly assigned (like a coin flip) to receive either the BOTOX® medicine or a saltwater (placebo) injection. Neither patients nor the care team will know which one was given. All participants will still have their planned hernia repair in the standard way that we repair patients who are not part of the study. The study will track whether the abdomen can be closed without leaving a gap, and investigators will also look at recovery, complications, time in the ICU or on a ventilator, length of stay, pain, and quality-of-life scores. Most information will be collected during participants' hospital stay, but the investigators will continue to see how participants are doing up to 2 years after surgery. Short phone check-ins will occur before surgery, and after surgery follow-up happens around 30 days, 90 days, 1 year, and 2 years. Possible risks from the injection include temporary muscle weakness, trouble swallowing or breathing, pain or infection at the injection site, and (if CT is used for guidance) a small amount of radiation exposure. Surgery itself carries the usual risks (pain, bleeding, wound problems). Benefits are not guaranteed, but the injection may make closure easier and recovery smoother. About 188 people will take part at Cleveland Clinic.
Primary Outcome
Primary fascial closure (PFC) is the successful closure of the hernia. It will be defined in a binary, categorical manner as: "Yes" (fascial closed) or "No" (fascia not closed and bridging mesh required). To be considered "Yes" for PFC, the midline anterior fascia must be completely re-approximated via absorbable running or figure-of-eight sutures. If any segment of the anterior fascia cannot be approximated and closed, the patient will require anterior bridging and this would be considered a fa
Conditions Studied
Interventions
- DRUG OnabotulinumtoxinA
- PROCEDURE OnabotulinumtoxinA Injection
- PROCEDURE Saline (placebo) Injection
- DRUG 0.9 % Normal Saline
- PROCEDURE Open Ventral Hernia Repair
Study Locations (1)
Ohio
- Cleveland Clinic Main Campus - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2029-12-15 |
| Phase | Phase 4 |
What NCT07220382 shows while recruiting
NCT07220382 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 186-participant average among 11 other Hernia trials with a reported enrollment target.
The record links to 7 conditions, with Hernia appearing as the primary indexed condition, and to 5 interventions - of which OnabotulinumtoxinA is the first listed.
NCT07220382 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07220382 about?
NCT07220382 is a clinical study titled "Preoperative BOTOX® Injection for Large Ventral Hernia Repair". This study is for adults who need open surgery to repair a very large abdominal (ventral) hernia. This study tests whether a one-time, image-guided injection of a medicine commonly known as "BOTOX®" (onabotulinumtoxinA) into the side abdominal muscles 3-7 weeks before surgery helps surgeons close th...
What is the current status of trial NCT07220382?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 188 participants. The study started on 2025-11-03. Estimated completion is 2029-12-15.
What conditions does trial NCT07220382 study?
This clinical trial studies the following conditions: Hernia, Hernia Abdominal Wall, Hernia Incisional Ventral, Hernia Incisional, Botox Injection.
What interventions are being tested in trial NCT07220382?
The interventions under investigation include: OnabotulinumtoxinA (DRUG), OnabotulinumtoxinA Injection (PROCEDURE), Saline (placebo) Injection (PROCEDURE), 0.9 % Normal Saline (DRUG), Open Ventral Hernia Repair (PROCEDURE).
Who is sponsoring clinical trial NCT07220382?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220382 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hernia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220382's enrollment target sits among peer trials
188 3rd of 11 higher than 9 of 11 other Hernia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hernia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Registry for Long-term Outcomes Following FETO in Severe Left and Right CDH
RECRUITING · NA
-
Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia
ACTIVE NOT RECRUITING · NA
-
Pilot Trial of Abdominal Core Rehabilitation To Improve Outcomes After Ventral Hernia Repair
ACTIVE NOT RECRUITING · NA
-
Assess the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant Laparoscopic Inguinal or Umbilical Herniorrhaphy
COMPLETED · Phase 2
-
Hernia Repair With or Without Sutures
COMPLETED · NA
-
Dominican Republic Mission Cost Analysis
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI